Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Assets (2019 - 2025)

Vivos Therapeutics (VVOS) has disclosed Assets for 7 consecutive years, with $25.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Assets rose 67.09% to $25.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $25.6 million, a 67.09% increase, with the full-year FY2024 number at $15.3 million, up 42.44% from a year prior.
  • Assets was $25.6 million for Q3 2025 at Vivos Therapeutics, down from $26.0 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $46.2 million in Q2 2021 to a low of $10.3 million in Q3 2023.
  • A 5-year average of $21.2 million and a median of $17.1 million in 2023 define the central range for Assets.
  • Peak YoY movement for Assets: tumbled 59.27% in 2022, then soared 67.09% in 2025.
  • Vivos Therapeutics' Assets stood at $33.7 million in 2021, then crashed by 59.27% to $13.7 million in 2022, then fell by 21.79% to $10.7 million in 2023, then surged by 42.44% to $15.3 million in 2024, then soared by 67.78% to $25.6 million in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Assets are $25.6 million (Q3 2025), $26.0 million (Q2 2025), and $11.3 million (Q1 2025).